Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ

$32.10

+0.91%
HealthcareBiotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.86B
EPS2.7600
P/E Ratio11.63
Earnings Date08/04/2026

hrmy

Total Current Liabilities

Last Annual Value

252.13M

3-Year CAGR

47%

5-Year CAGR

13%

10-Year CAGR

43%

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Competitors Analysis of Total Current Liabilities

HRMY · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
252.13M
15.5%36.2%N/A 
171.03M
18.0%28.7%6.4%
BHVN logo
Biohaven Ltd.
NYSE:BHVN
115.93M
27.9%22.6%N/A
11.71M
13.4%N/AN/A
50.99M
17.9%25.3%3.8%
25.00M
24.2%14.3%N/A
82.23M
80.5%37.2%N/A
53.45M
33.8%47.4%N/A
Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Fair Value Envelope

HRMY · NASDAQ

Our analysis suggests that HRMY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.1, this represents a potential HIDDEN relative to our calculated worth for Harmony Biosciences Holdings, Inc..

Intrinsic Value
Current Price: $32.1